Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GSKGLAXF +3.55%69 Days Sales Outstanding is 83.89 as of Jun. 2026, which is 28% above its 10-year median of 65.41. GuruFocus rates GLAXF with a GF Score™ of 69/100 and a GF Value™ of $21.64 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 949 Drug Manufacturers companies, GSK ranks worse than 57.74% on this metric.
GSK's average Accounts Receivable for the
three
months ended in Jun. 2026 was $10,308 Mil. GSK's Revenue for the
three
months ended in Jun. 2026 was $11,212 Mil.
Hence, GSK's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 83.89.
The historical rank and industry rank for GSK's Days Sales Outstanding or its related term are showing as below:
GLAXF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 55.22 Med: 65.41 Max: 87.16
Current: 80.54
During the past 13 years, GSK's highest Days Sales Outstanding was 87.16. The lowest was 55.22. And the median was 65.41.
GLAXF's Days Sales Outstanding is ranked worse than 57.74% of 949
companies
in the Drug Manufacturers industry
Industry Median: 72
vs GLAXF: 80.54
GSK's Days Sales Outstanding
increased
from Jun. 2025 (80.23) to Jun. 2026 (83.89).
GSK (OTCPK:GLAXF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
GSK Days Sales Outstanding Related Terms
GSK Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for GSK's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GLAXF vs LLY, JNJ, ABBV: Days Sales Outstanding Comparison
For the Drug Manufacturers - General subindustry, GSK's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GSK Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GSK's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where GSK's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GSK (GLAXF) has a Days Sales Outstanding of 83.89 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on GSK and its competitors. This is 28% above median its historical median of 65.41. Over the past decade, GSK's Days Sales Outstanding has ranged from 55.22 to 87.16. According to the industry distribution chart, GSK ranks #548 out of 949 companies in the Drug Manufacturers industry, placing it in the top 57.7%.
Is GSK's Days Sales Outstanding too high?
GSK's current Days Sales Outstanding of 83.89 is 28% above median its 10-year median of 65.41. Over the past 10 years, this metric has ranged from a low of 55.22 to a high of 87.16. The Drug Manufacturers industry median Days Sales Outstanding is 72.00. GSK's value of 83.89 is 16.5% above this industry median. Based on the distribution chart, GSK ranks #548 out of 949 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, GSK has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's Days Sales Outstanding compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #548 out of 949 companies for Days Sales Outstanding. This places GSK in the lower half of its industry. The industry median Days Sales Outstanding is 72.00. GSK's value of 83.89 is 16.5% above this benchmark. Historically, GSK's own Days Sales Outstanding has ranged from 55.22 to 87.16 over the past decade. While the company's 10-year median is 65.41 vs. the industry median of 72.00, GSK has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 72.00, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GSK's current Days Sales Outstanding of 83.89 is 16.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on GSK and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 72.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GSK's current Days Sales Outstanding is 83.89, which is 28% above median its own 10-year median of 65.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.64, compared to a current price of $27.00 — trading 24.8% above its estimated fair value. The current Days Sales Outstanding is 83.89, which is 28% above median its 10-year median of 65.41 and 16.5% above the Drug Manufacturers industry median of 72.00. GSK's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For GSK (GLAXF), the current Days Sales Outstanding is 83.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GSK (GLAXF) Overvalued in 2026?
Based on GuruFocus' analysis, GSK stock appears to be overvalued.
The current stock price of $27.00 is trading 24.8% above its estimated GF Value™ of $21.64.
GuruFocus considers GSK to be Modestly Overvalued.
Key valuation signals for GLAXF:
Days Sales Outstanding: 83.89 (28% above median its 10-year median of 65.41)
GF Value™: $21.64 vs. price of $27.00 (24.8% above fair value)
Industry Position: 16.5% above the Drug Manufacturers median (#548 of 949)
No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
69GF Score
Get the complete analysis for GLAXF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLAXF has been successfully added to your 
